Quantitative muscle MRI: A powerful surrogate outcome measure in Duchenne muscular dystrophy

Bonati U, Hafner P, Schädelin S, Schmid M, Naduvilekoot Devasia A, Schroeder J, Zuesli S, Pohlman U, Neuhaus C, Klein A, Sinnreich M, Haas T, Gloor M, Bieri O, Fischmann A, Fischer D.
Neuromuscul Disord. 2015. 25(9):679-85.
This prospective one year observational study compared quantitative muscle MRI (qMRI) with clinical scores in DMD.
In 20 DMD patients, MFM total and subscores (D1, D2 and D3) were compared to the fat fraction (MFF) of thigh muscle qMRI obtained using the two-point Dixon method.
QMRI shows pathophysiological changes in DMD and might serve as a surrogate outcome measure in clinical trials.

PubMed link

Keywords: Duchenne muscular dystrophy, Outcome measure, Endpoint, Quantitative MRI, Neuromuscular disorders

Articles dans les revues scientifiques

Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial)

Stam M, Wadman RI, Wijngaarde CA, Bartels B, Asselman FL, Otto LAM, Goedee HS, Habets LE, de Groot JF, Schoenmakers MAGC, Cuppen I, van den Berg LH, van der Pol WL. BMJ Open. 2018. 30;8(7):e019932.  Protocol of the "SPACE" in wich MFM is used as an outcome measure....

read more